Emily Bergsland, MD

Education
2019 - Diversity, Equity, and Inclusion Champion Training, University of California
06/1998 - Molecular Medicine Training Program, University of California (UCSF)
Fellowship, 06/1995 - Medical Oncology, University of California (UCSF)
06/1993 - Chief Residency, University of California (UCSF)
Residency, 06/1992 - Internal Medicine, University of California (UCSF)
MD, 06/1989 - Medicine, University of Minnesota
BS, 05/1985 - Biochemistry/Molecular Biology, University of Wisconsin
Websites
Publications

  1. Moradpour M, Moradi Tochayi A, Houshmand S, Nwihim S, Jiang F, Yadav S, Lindsay S, Bergsland EK, Hope TA. Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026. PMID: 41956562


  2. Yogo A, Akanuma N, Kim GE, Paciorek A, Zhang L, Le P, Hirose K, Corvera CU, Bergsland EK, Nakakura EK. Characterization of small intestinal neuroendocrine tumorlets. Endocrine-related cancer 2026. PMID: 41886547


  3. Expert Panel on Gastrointestinal Imaging, Yacoub JH, Yano M, Chang KJ, Bergsland E, Bhosale PR, Cash BD, Chernyak V, Gupta A, Hallet J, Halpern J, Magnetta M, Noronha CF, Refaat T, Korngold EK. ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors. Journal of the American College of Radiology : JACR 2026. PMID: 41823937


  4. Choucair A, Zdunek A, Liao M, Bodei L, Deandreis D, Das J, Barbe R, Bergsland E, Geyer S, Bidault F, Garcia G, Yeh R, Balleyguier C, Lassau N, Dercle L, Ammari S. Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management. Insights into imaging 2026. PMID: 41661399


  5. de Mestier L, Halfdanarson TR, Apostolidis L, Koumarianou A, Hernando J, Riechelmann R, Bergsland EK, Cingarlini S, Shaheen S, Crona J, Kreutzfeldt S, Mosalem O, Al-Toubah T, Cros J, Strosberg JR. Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy. Endocrine pathology 2025. PMID: 41182464


  6. Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025. PMID: 40902132


  7. Miao X, Su P, Ohliger MA, Yang Y, Pang J, Hotca AE, Hope TA, Hong CW, Bergsland EK, Feng M, Scholey JE. 4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning. Medical physics 2025. PMID: 40903915


  8. Riechelmann RP, Torrezan GT, Bergsland E, Raj N, Strosberg J, Moon F, Felismino TC, Knappskog S, Trevizani E, Cingarlini S, Sorbye H. Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study. Therapeutic advances in medical oncology 2025. PMID: 40727887


  9. Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies Consortium Group. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer 2025. PMID: 40558053


  10. Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies (PSM) Consortium Group. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms. Annals of surgical oncology 2025. PMID: 40560496


  11. Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland EK. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO oncology practice 2025. PMID: 40344544


  12. Casey M, Tozzi F, Wang J, Park KM, Bergsland E, Hope T, Kennecke HF, Rose JB, Babicky M, Irani SS, El-Hayek KM, Hilal MA, Asbun HJ, Cleary S, Smeets P, Berrevoet F, Adam M, Rashidian N, Alseidi A, PNET Diagnosis Research Group. Appropriate use of tissue sampling and somatostatin receptor PET imaging in the diagnosis of pancreatic neuroendocrine tumors: results of an International Delphi Consensus. Surgical endoscopy 2025. PMID: 40316747


  13. Hong CW, Yang Y, Remick I, Su P, Itriago-Leon P, Nickel MD, Fautz HP, Majeed W, Bergsland E, Hope TA, Ohliger MA. Flip Angle Optimization for Hepatobiliary Phase MRI at 0.55 T in Patients With Metastatic Neuroendocrine Tumors: A Prospective Study. AJR. American journal of roentgenology 2025. PMID: 40237428


  14. Masharani U, Lindsay S, Moon F, Paciorek A, Bergsland E. Metastatic insulinoma-outcomes in the current era. The oncologist 2024. PMID: 39475415


  15. Paciorek A, Mulvey C, McKinley M, Zhang L, Cheng I, Moon F, Le BK, Shih BE, Whitman J, Bergsland E. Burdens of Gastroenteropancreatic Neuroendocrine Neoplasm by Diverse Race and Ethnicities- A Rigorous Structural Equation Modeling. Journal of the National Comprehensive Cancer Network : JNCCN 2025. PMID: 39938473


  16. Wang SJ, Kidder W, Joseph NM, Le BK, Lindsay S, Moon F, Nakakura E, Zhang L, Bergsland EK. Factors associated with grade progression in pancreatic neuroendocrine tumors. Endocrine-related cancer 2025. PMID: 39813097


  17. Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, Kakar S. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Endocrine pathology 2024. PMID: 39556303


  18. Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. JCO precision oncology 2024. PMID: 39509670


  19. Chin A, Lindsay S, Bergsland EK, Kang H. Withdrawal pain following patients discontinuing Trk inhibitors. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2024. PMID: 39191376


  20. Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kaleblasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Research Communications 2024. PMID: 38920407


  21. Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO precision oncology 2024. PMID: 38865673


  22. Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. Annals of surgical oncology 2024. PMID: 38797790


  23. Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA: a cancer journal for clinicians 2024. PMID: 38685134


  24. Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center. The oncologist 2023. PMID: 37440206


  25. Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R, Bergsland EK, Hope TA. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024. PMID: 38428966


  26. Mulvey CK, Paciorek A, Moon F, Steiding P, Shih B, Gubens MA, Zhang L, Bergsland EK, Cheng I. Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors. Endocrine-related cancer 2023. PMID: 37882324


  27. Sada A, Foster TR, Al-Ward R, Sawani S, Charchar H, Pishdad R, Ben-Shlomo A, Dy BM, Lyden ML, Bergsland E, Jasim S, Raj N, Shank JB, Hamidi O, Hamrahian AH, Chambô JL, Srougi V, Fragoso MC, Graham PH, Habra MA, Bancos I, McKenzie TJ. The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study. Surgery 2023. PMID: 37945477


  28. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023. PMID: 37774329


  29. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, NET CTPM participants. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. Journal of the National Cancer Institute 2023. PMID: 37255328


  30. Majmudar S, Graff SL, Kays M, Braz BX, Matt-Amaral L, Markham MJ, Subbiah IM, Bergsland E, Jain S. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow. Journal of medical Internet research 2023. PMID: 37603399


  32. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovittz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Consensus recommendations for management of high grade neuroendocrine tumors. Endocrine-related cancer 2023. PMID: 37184955


  33. Sedlack AJH, Hatfield SJ, Kumar S, Arakawa Y, Roper N, Sun NY, Nilubol N, Kiseljak-Vassiliades K, Hoang CD, Bergsland EK, Hernandez JM, Pommier Y, Del Rivero J. Preclinical Models of Adrenocortical Cancer. Cancers 2023. PMID: 37296836


  34. Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. British journal of cancer 2023. PMID: 37208512


  35. Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. Journal of neuroendocrinology 2023. PMID: 37002881


  36. Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review. Clinical genitourinary cancer 2023. PMID: 37031047


  37. Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis. European journal of cancer (Oxford, England : 1990) 2023. PMID: 36738541


  38. Umetsu SE, Kakar S, Basturk O, Kim GE, Chatterjee D, Wen KW, Hale G, Shafizadeh N, Cho SJ, Whitman J, Gill RM, Jones KD, Navale P, Bergsland E, Klimstra D, Joseph NM. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023. PMID: 36788102


  39. Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J. Preclinical Models of Neuroendocrine Neoplasia. Cancers 2022. PMID: 36428741


  40. Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. The oncologist 2022. PMID: 35983951


  41. Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Research Communications 2022. PMID: 36923283


  42. Sun F, Grenert JP, Tan L, Van Ziffle J, Joseph NM, Mulvey CK, Bergsland E. Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung. JCO precision oncology 2022. PMID: 35737914


  43. Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022. PMID: 35649195


  44. Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, Bhosale P, Yano M. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. Abdominal radiology (New York) 2022. PMID: 35244755


  45. Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021. PMID: 34936379


  46. Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss PS, Posadas EM, Donahue T, Hecht JR, Allen-Auerbach MS, Bergsland EK, Hope TA, Pei R, Zhu Y, Tseng HR, Heaney AP. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. Biosensors & bioelectronics 2021. PMID: 34896918


  47. Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021. PMID: 34736838


  48. Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. The oncologist 2021. PMID: 34342086


  49. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 34340212


  50. Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. PloS one 2021. PMID: 34077464


  51. Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, Pommier Y, Del Rivero J. The Immunotherapy Landscape in Adrenocortical Cancer. Cancers 2021. PMID: 34071333


  52. Hörsch D, Anthony L, Gross DJ, Valle JW, Welin S, Benavent M, Caplin M, Pavel M, Bergsland E, Öberg K, Kassler-Taub KB, Binder P, Banks P, Lapuerta P, Kulke MH. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. Neuroendocrinology 2021. PMID: 33940581


  53. Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas 2021. PMID: 33939661


  54. Mahuron KM, Kasai Y, Javeed ZA, Bergsland EK, Hirose K, Corvera CU, Nakakura EK. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021. PMID: 33742361


  55. Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocrine-related cancer 2021. PMID: 33480358


  56. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. Journal of gastrointestinal cancer 2021. PMID: 32146619


  57. Whitman J, Allen IE, Bergsland EK, Suh I, Hope TA. Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021. PMID: 33452040


  58. Maddali MV, Chiu C, Cedarbaum ER, Yogeswaran V, Seedahmed M, Smith W, Bergsland E, Fidelman N, Kennedy JLW. Carcinoid Crisis-Induced Acute Systolic Heart Failure. JACC. Case reports 2020. PMID: 34317110


  59. Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdominal radiology (New York) 2020. PMID: 33095312


  60. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020. PMID: 32675783


  61. Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020. PMID: 32663527


  62. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas 2020. PMID: 32433264


  63. Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, Pavel M, Reidy-Lagunes D, Siveke J, Strosberg J, Dittmer U, Herrmann K. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns? Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020. PMID: 32576637


  64. Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. Reply to S. Boutayeb et al. JCO oncology practice 2020. PMID: 32574129


  65. Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, Lindsay S, Bergsland EK, Hope TA. Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020. PMID: 32513903


  66. Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. JCO oncology practice 2020. PMID: 32352884


  67. Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer 2020. PMID: 32320048


  68. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors. Journal of surgical oncology 2020. PMID: 32291778


  69. Strosberg J, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 31980466


  70. Wang TS, Bergsland EK, Zhang R, Ihnken K, Tolstrup K. A Rare Case of Carcinoid Constrictive Pericarditis. JACC. Case reports 2020. PMID: 34316954


  71. Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis. Journal of surgical oncology 2019. PMID: 31828813


  72. Whitman J, Kardosh A, Diaz L, Fong L, Hope T, Onodera C, Joseph N, Le D, Fisher G, Bergsland E. Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma. JCO precision oncology 2019. PMID: 35100735


  73. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. Journal of gastrointestinal cancer 2019. PMID: 30058032


  74. Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. Journal of patient-reported outcomes 2019. PMID: 31655936


  75. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors. Journal of surgical oncology 2019. PMID: 31613999


  76. Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, Van Loon K, Hope TA. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors. Pancreas 2019. PMID: 31268975


  77. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PloS one 2019. PMID: 31291332


  78. Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruíz-García E, You YN, Baxter N. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019. PMID: 30986117


  79. Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases. Pancreas 2019. PMID: 30946246


  80. Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. The oncologist 2019. PMID: 30651397


  81. Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases. Translational oncology 2019. PMID: 30639964


  82. Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. The oncologist 2019. PMID: 30610008


  83. Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. The oncologist 2019. PMID: 30606883


  84. Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E, Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA oncology 2018. PMID: 30054622


  85. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Molecular cancer therapeutics 2018. PMID: 30254185


  86. Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho SJ, Saunders TA, Jen KY, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018. PMID: 30237525


  87. Mulvey CK, Bergsland EK. Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors. Journal of oncology practice 2018. PMID: 30096272


  88. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 29891520


  89. Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clinical therapeutics 2018. PMID: 29724499


  90. Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. Clinical therapeutics 2017. PMID: 29074312


  91. Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017. PMID: 29025982


  92. Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Familial cancer 2017. PMID: 28283864


  93. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 2017. PMID: 28609356


  94. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas 2017. PMID: 28609357


  95. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. The oncologist 2017. PMID: 28507205


  96. Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. Medical oncology (Northwood, London, England) 2017. PMID: 28393314


  97. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. Journal for immunotherapy of cancer 2017. PMID: 28344808


  98. Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas 2017. PMID: 28187108


  99. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. Journal of gastrointestinal oncology 2016. PMID: 28078110


  100. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas 2016. PMID: 27171514


  101. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016. PMID: 27918724


  102. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. A phase II study of axitinib in advanced neuroendocrine tumors. Endocrine-related cancer 2016. PMID: 27080472


  103. Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen CT, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Annals of surgical oncology 2016. PMID: 27020587


  104. Mulvey CK, Bergsland EK. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. Hematology/oncology clinics of North America 2016. PMID: 26614369


  105. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research 2015. PMID: 26603258


  106. Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. EJNMMI physics 2015. PMID: 26501822


  107. Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdominal imaging 2015. PMID: 25820755


  108. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer 2015. PMID: 26177599


  109. Heidecker B, Moore P, Bergsland EK, Merrick SH, Rao RK. Transcatheter pulmonic valve replacement in carcinoid heart disease. European heart journal. Cardiovascular Imaging 2015. PMID: 26003151


  110. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell reports 2015. PMID: 25892230


  111. Bergsland EK. Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015. PMID: 25646187


  112. Bergsland EK. Is more not better?: combination therapies in colorectal cancer treatment. Hematology/oncology clinics of North America 2015. PMID: 25475574


  113. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D, National comprehensive cancer network. Neuroendocrine tumors, version 1.2015. Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 25583772


  114. Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2015. PMID: 25993147


  115. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocrine connections 2014. PMID: 25430999


  116. Bergsland EK, Nakakura EK. Neuroendocrine tumors of unknown primary: is the primary site really not known? JAMA surgery 2014. PMID: 25029597


  117. Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocrine-related cancer 2014. PMID: 25012985


  118. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer cell 2014. PMID: 24909985


  119. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. Journal of gastrointestinal cancer 2014. PMID: 24448917


  120. Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland EK. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer chemotherapy and pharmacology 2014. PMID: 24488322


  121. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. British journal of cancer 2013. PMID: 24022191


  122. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2013. PMID: 23542178


  123. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Annals of oncology : official journal of the European Society for Medical Oncology 2013. PMID: 23519998


  125. Bergsland EK. The evolving landscape of neuroendocrine tumors. Seminars in oncology 2013. PMID: 23391109


  126. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. American journal of clinical oncology 2012. PMID: 21552099


  127. Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas 2012. PMID: 22781907


  128. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA, National Comprehensive Cancer Networks. Neuroendocrine tumors. Journal of the National Comprehensive Cancer Network : JNCCN 2012. PMID: 22679117


  129. Paulson AS, Bergsland EK. Systemic therapy for advanced carcinoid tumors: where do we go from here? Journal of the National Comprehensive Cancer Network : JNCCN 2012. PMID: 22679120


  130. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Investigational new drugs 2012. PMID: 22270257


  131. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM, Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Annals of surgery 2011. PMID: 21494121


  132. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011. PMID: 21263089


  133. Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. The Journal of surgical research 2010. PMID: 20599218


  134. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Archives of surgery (Chicago, Ill. : 1960) 2010. PMID: 20231629


  135. Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocrine-related cancer 2010. PMID: 20048018


  136. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer chemotherapy and pharmacology 2010. PMID: 20130876


  137. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. The New England journal of medicine 2009. PMID: 19129539


  138. Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocrine-related cancer 2008. PMID: 18987169


  140. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008. PMID: 18612155


  141. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Investigational new drugs 2008. PMID: 18379729


  142. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer investigation 2008. PMID: 18181045


  143. Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clinical colorectal cancer 2008. PMID: 18279576


  144. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007. PMID: 17947727


  145. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute 2007. PMID: 17686822


  146. Nakakura EK, Venook AP, Bergsland EK. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer? Surgical oncology clinics of North America 2007. PMID: 17606198


  147. Nakakura EK, Bergsland EK. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. Hematology/oncology clinics of North America 2007. PMID: 17548034


  148. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics 2007. PMID: 17363191


  149. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006. PMID: 16877721


  150. Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK. Pancreatoblastoma in an adult: case report and review of the literature. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2006. PMID: 16769539


  151. Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H. Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer metastasis reviews 2006. PMID: 16770540


  152. Bergsland EK. When does the presence of the target predict response to the targeted agent? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 16365177


  153. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 16344320


  154. Whisenant J, Bergsland E. Anti-angiogenic strategies in gastrointestinal malignancies. Current treatment options in oncology 2005. PMID: 16107244


  155. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer 2005. PMID: 15999098


  156. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 15867200


  157. Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2005. PMID: 15756001


  158. Bergsland EK. Update on clinical trials targeting vascular endothelial growth factor in cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2004. PMID: 15552622


  159. Bergsland EK. Vascular endothelial growth factor as a therapeutic target in cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2004. PMID: 15552621


  160. Allen J, Bergsland EK. Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematology/oncology clinics of North America 2004. PMID: 15474337


  161. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. The oncologist 2004. PMID: 15178814


  162. Mohr DC, Moran PJ, Kohn C, Hart S, Armstrong K, Dias R, Bergsland E, Folkman S. Couples therapy at end of life. Psycho-oncology 2003. PMID: 12923802


  163. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. The Journal of clinical investigation 2003. PMID: 12727920


  164. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. The Journal of experimental medicine 2003. PMID: 12695493


  165. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003. PMID: 12506171


  166. Ko AH, Bergsland EK, Lee GA. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature. Digestive diseases and sciences 2003. PMID: 12645810


  167. Bergsland EK, Venook AP. Shedding old paradigms: developing viruses to treat cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002. PMID: 11980991


  168. Bergsland EK. Molecular mechanisms underlying the development of hepatocellular carcinoma. Seminars in oncology 2001. PMID: 11685745


  169. Bergsland EK, Venook AP. Hepatocellular carcinoma. Current opinion in oncology 2000. PMID: 10888422


  170. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. The Journal of clinical investigation 2000. PMID: 10772648


  171. Bullard KM, Banda MJ, Arbeit JM, Bergsland E, Young DM. Human acellular dermal matrix as a novel model of malignant epithelial cell invasion. Invasion & metastasis 1997. PMID: 9425323